Last reviewed · How we verify
Tritanrix-HepB/Meningitec conjugate vaccine
Tritanrix-HepB/Meningitec conjugate vaccine is a Conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Protection against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y in infants and young children. Also known as: DTPw-HBV/Hib-MenAc conjugate vaccine, DTPw-HBV/Hib-MenAC conjugate vaccine.
Tritanrix-HepB/Meningitec conjugate vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y.
Tritanrix-HepB/Meningitec conjugate vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y in infants and young children.
At a glance
| Generic name | Tritanrix-HepB/Meningitec conjugate vaccine |
|---|---|
| Also known as | DTPw-HBV/Hib-MenAc conjugate vaccine, DTPw-HBV/Hib-MenAC conjugate vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains inactivated or killed pathogens and antigens from the listed diseases. Upon administration, the antigens are recognized by the immune system, triggering a response that produces antibodies to neutralize or remove the pathogens. This provides long-term immunity against the diseases.
Approved indications
- Protection against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y in infants and young children
Common side effects
- Injection site pain
- Fever
- Vomiting
Key clinical trials
- Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m (PHASE3)
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tritanrix-HepB/Meningitec conjugate vaccine CI brief — competitive landscape report
- Tritanrix-HepB/Meningitec conjugate vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Tritanrix-HepB/Meningitec conjugate vaccine
What is Tritanrix-HepB/Meningitec conjugate vaccine?
How does Tritanrix-HepB/Meningitec conjugate vaccine work?
What is Tritanrix-HepB/Meningitec conjugate vaccine used for?
Who makes Tritanrix-HepB/Meningitec conjugate vaccine?
Is Tritanrix-HepB/Meningitec conjugate vaccine also known as anything else?
What drug class is Tritanrix-HepB/Meningitec conjugate vaccine in?
What development phase is Tritanrix-HepB/Meningitec conjugate vaccine in?
What are the side effects of Tritanrix-HepB/Meningitec conjugate vaccine?
Related
- Drug class: All Conjugate vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Protection against diphtheria, tetanus, pertussis, hepatitis B, and meningococcal serogroups A, C, W, and Y in infants and young children
- Also known as: DTPw-HBV/Hib-MenAc conjugate vaccine, DTPw-HBV/Hib-MenAC conjugate vaccine
- Compare: Tritanrix-HepB/Meningitec conjugate vaccine vs similar drugs
- Pricing: Tritanrix-HepB/Meningitec conjugate vaccine cost, discount & access